منابع مشابه
COX-2 inhibitors and breast cancer.
The cyclooxygenase ( COX ) -2 inhibitor celecoxib was recently approved in the USA for the prevention of polyp formation in familial adenomatous polyposis, a defined premalignant condition for colorectal cancer. The potential value of COX inhibitors in similar roles for other malignancies, particularly breast cancer, is therefore currently under intense scrutiny. Use of these medications in che...
متن کاملCOX-2 Inhibitors and Gastric Cancer
The evidence that cyclooxygenase-2 (COX-2) is upregulated and plays an important role in carcinogenesis of gastric cancer has triggered the topic of COX-2 inhibitors as chemopreventive agents for gastric cancer. Studies find that COX-2 inhibitors are associated not only with chemoprophylactic effects, but also with chemotherapeutic potentials in gastric cancer. Both COX-dependent and COX-indepe...
متن کاملFluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.
COX-2 is a major contributor to the inflammatory response and cancer progression so it is an important target for prevention and therapy. COX-2 is absent or expressed at low levels in most epithelial cells but is found at high levels in inflammatory lesions, and many premalignant and malignant tumors. Thus, it is an attractive target for molecular imaging. We report a series of novel fluorinate...
متن کاملCOX-2 inhibitors.
Cyclooxygenase-2 (COX-2) inhibitors constitute a new group of non-steroidal anti-inflammatory drugs (NSAIDs) which, at recommended doses, block prostaglandin production by cyclooxygenase-2, but not by cyclooxygenase-1. Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once daily. Both drugs act rapidly in providing pa...
متن کاملCOX-2 inhibitors in prostate cancer treatment--hold your horses?
yclo-oxygenase has been implicated as a potential therapeutic target in prostate cancer. However, the ongoing multi-arm randomized controlled STAMPEDE trial has failed to show a benefit of the cyclo-oxygenase 2 inhibitor celecoxib in men with locally advanced or metastatic prostate cancer also receiving androgen deprivation therapy. STAMPEDE uses a novel adaptive design that allows testing of d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Integrative Cancer Therapies
سال: 2005
ISSN: 1534-7354,1552-695X
DOI: 10.1177/1534735405274664